secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0001193125-22-301836
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics amends bylaws for universal proxy rules and DGCL updates
-------------------------------------------------------------------------------

- Enhanced disclosure requirements for stockholder nominations, including questionnaires and nominee resignation agreements.
- Added provisions for Universal Proxy Rules (Rule 14a-19), requiring intent disclosure and evidence of compliance.
- Clarified board authority to determine if nominations/proposals properly brought and to postpone/cancel meetings.
- Updated provisions for remote meetings and adjournment procedures per recent DGCL amendments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522301836/0001193125-22-301836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312522301836/d514100d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-301836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer